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Summary
Background: Contrast-induced nephropathy (CIN) is one of the important complications of coro-
nary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients
with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and
aminophylline has been reported to be effective in some trials, but the results still remain
controversial. We investigated the efﬁcacy of NAC or aminophylline in preventing CIN.
Methods and results: Forty-ﬁve consecutive patients undergoing CAG and/or PCI were ran-
domly assigned to receive hydration and NAC (704mg orally twice daily; NAC group, n = 15),
hydration and aminophylline (250mg intraveneously 30min before CAG and/or PCI; amino-
phylline group, n = 15), or hydration alone (control group, n = 15). We compared serum creatinine
(SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobu-
lin levels at baseline and 48 h after CAG and/or PCI. In the NAC group, SCr decreased from
1.00± 0.36 to 0.67± 0.16mg/dl (p < 0.01), and Ccr signiﬁcantly increased from 62.4± 15.6 to
80.4± 8.39ml/min (p < 0.01). In the aminophylline group, SCr and Ccr were unchanged. In the
control group, SCr signiﬁcantly increased from 0.94± 0.21 to 1.28± 0.21mg/dl (p < 0.01), and
Ccr signiﬁcantly decreased from 63.7± 16.1 to 46.1± 10.6ml/min (p < 0.01) after CAG and/or
PCI. In the NAC group, mean blood beta-2 microglobulin signiﬁcantly decreased from 2.38± 0.58
to 1.71± 0.38mg/dl (p < 0.01), and in the aminophylline group, mean urinary beta-2 microglob-
ulin concentration signiﬁcantly decreased from 337± 31.0 to 239± 34g/ml (p < 0.01).
∗ Corresponding author. Tel.: +81 83 241 1199; fax: +81 83 241 1301.
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Conclusions: These results suggest that both prophylactic NAC and aminophylline administration
are effective in preventing CIN, but not with hydration alone. It appears that the two compounds
st CIN
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catheter was used for PCI. All patients received iopamidol
(Oypalomin, Konica Minolta, Tokyo, Japan) as their contrastwork in different ways again
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Introduction
Contrast-induced nephropathy (CIN) is a signiﬁcant compli-
cation after coronary angiography (CAG) and percutaneous
coronary intervention (PCI) that has been associated with
prolonged hospitalization and adverse clinical outcomes
[1—3]. Ongoing advances in catheter-based technologies
for the treatment of coronary artery disease (CAD) have
been accompanied by a steady increase in the use of PCI.
Patients with renal disease also frequently have critical CAD
and require PCI. Therefore, renal complications after PCI
become increasingly important as a cause of periprocedural
morbidity and mortality [4]. The best approach to CIN is pre-
vention, and efﬁcacious and safe prophylactic prevention of
CIN should decrease morbidity and mortality during hospi-
talization, including the need for dialysis, and thus reduce
medical costs.
Renal free-radical production increases after the admin-
istration of a contrast medium [5], and reactive oxygen
species have a role in CIN [5—8]. In animal studies, super-
oxide dismutase, a scavenger of reactive oxygen species,
prevents renal damage with contrast agents [5]. Recently
Tepel et al. [7] reported that N-Acetylcysteine (NAC), an
antioxidant, prevented CIN, and Diaz-Sandoval et al. [8] also
reported the beneﬁcial effect of NAC on preventing CIN in
patients undergoing CAG.
Adenosine, another key mediator of CIN, has been
suggested as a possible candidate for mediating renal vaso-
constriction after contrast-media administration in animal
studies [9]. This postulate is derived from the observation
that adenosine can induce afferent arteriolar vasoconstric-
tion and a fall in glomerular ﬁltration rate after intrarenal
injection and infusion in rats and dogs [10—14]. Several clin-
ical studies have investigated the competitive adenosine
antagonist aminophylline as a prophylaxis [15—20].
The pathogenesis of CIN is not fully understood. How-
ever, prophylactic administration of NAC and aminophylline
has previously been reported to be effective, although the
results still remain controversial [7,8,15—29]. There are few
reports investigating the efﬁcacy of NAC and aminophylline
in Japanese patients with normal renal function. We inves-
tigated the efﬁcacy of NAC and aminophylline in preventing
CIN in patients undergoing CAG and/or PCI in patients under-
going CAG and/or PCI.
Subjects and methods
Patients
Between April 1, 2006, and March 31, 2007, all consecutive
patients who were admitted to our hospital, Kanmon Med-
ical Center in Japan, with stable coronary artery disease
who underwent CAG and/or PCI, and with stable serum cre-
atinine concentrations were included in the study. Stable
serum creatinine concentration was deﬁned as a difference
a
c
d
r
f.
ology. Published by Elsevier Ireland Ltd. All rights reserved.
f0.1mg/dl between baseline serum creatinine at 12—24 h
efore CAG and/or PCI. Serum creatinine was measured at
—2 weeks before CAG and/or PCI. Exclusion criteria of
his study included acute myocardial infarction requiring
rimary or rescue PCI, use of vasopressors before PCI, car-
iogenic shock, current peritoneal dialysis or hemodialysis,
lanned post-contrast dialysis, or allergies to the med-
cations being studied. We did not enroll patients with
vert congestive heart failure, severe valvular disease, or
dvanced severe left ventricular dysfunction, deﬁned as a
eft ventricular ejection fraction of less than 30%. Further
xclusion criteria were pregnancy, multiple myeloma and
myloidosis. The use of diuretics or nephrotoxic medica-
ions was not restricted. All patients were encouraged to
rink, if they were thirsty. Informed consent was obtained
rom all patients and this study protocol was approved by
he hospital’s Ethics Committee.
tudy protocol
he patients were randomly assigned to receive either NAC
nd intravenous saline (NAC group), and intravenous amino-
hylline and saline (aminophylline group) or intravenous
aline alone (control group). NAC (Mucoﬁlin, Eisai, Tokyo,
apan) was given orally at a dose of 704mg twice a day, the
ay before and on the day of CAG and/or PCI, for a total of 2
ays. Aminophylline (Neophylline, Eisai, Tokyo, Japan) was
iven intravenously at a dose of 250mg as a short infusion
100ml saline, 0.9%) 30min before CAG and/or PCI. Saline
0.9%) was given intravenously at a rate of 1ml/kg body
eight per hour for 30min before and 10 h after angiogra-
hy. Serum creatinine (SCr), blood urea nitrogen (BUN), and
lood beta-2 microglobulin were measured 12—24 h before
ngiography, and 48 h after angiography. Urinary beta-2
icroglobulin was measured 24 h before angiography, and
8 h after angiography. Creatinine clearance (Ccr) was con-
rmed by collection of urinary creatinine over 24 h. Ccr
as also measured 24 h before angiography, and 48 h after
ngiography.
AG and/or PCI
ingle-plane coronary angiography with or without angio-
lasty was performed according to standard clinical
ractice, using the transbrachial or transradial approach.
5F catheter was used for diagnostic CAG, and a 6Fgent. The iopamidol content was 0.755 g/ml, and the iodine
ontent was 370mg/ml. The dose of contrast agent was
ecided by each cardiologist. Patients who underwent PCI
eceived a bolus of 5000U heparin during the procedure,
ollowed by an additional bolus, if deemed necessary.
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Table 1 Baseline patient characteristics.
Characteristics Control group (n = 15) Aminophyline group (n = 15) NAC group (n = 15) p-Value
Age (years) 70± 8 71± 3 70± 10 0.734
Gender (M/F, n) 9/6 10/5 9/6 0.900
Body mass index (kg/m2) 22.1± 2.1 22.8± 2.2 224± 2.3 0.739
Systolic blood pressure (mmHg) 140± 14 144± 13 144± 16 0.478
Diastolic blood pressure (mmHg) 70± 8 72± 8 72± 8 0.675
Left ventricular ejection fraction (%) 63± 7 62± 9 63± 12 0.863
Hypertension 12 (80%) 13(87%) 13(87%) 0.844
Diabetes mellitus 6 (40%) 6(40%) 7 (47%) 0.910
Dyslipidemia 7 (47%) 7 (47%) 8(53%) 0.909
Diuretic therapy 4 (26%) 4(26%) 5(33%) 0.893
Calcium-channel blocker therapy 10 (67%) 11(73%) 11 (73%) 0.895
Angiotensin II receptor antagonist 6 (40%) 8(53%) 7 (47%) 0.765
Dose of contrast agent (ml) 141± 14 142± 15 147± 23 0.134
PCI/CAG (n) 6/9 7/8 7/8 0.687
BUH (mg/dl) 12.0± 2.5 13.1± 3.6 13.8± 34 0.195
SCr (mg/dl) 0.94± 0.21 0.97± 0.29 1.00± 0.36 0.919
Ccr (ml/min) 63.7± 16.1 63.4± 18.9 62.4± 15.6 0.884
Blood beta-2 microglobulin (mg/dl) 2.34± 048 23.37± 0.28 238± 0.58 0.828
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mUrinary beta-2 microglobulin (g/ml) 333± 99.7
PCI, perculaneous coronary intervention; CAG, coronary angiogra
clearance.
tatistical analysis
ll results are expressed as the mean± standard devia-
ion (SD). The Differences between the 3 groups were
etermined using the Kruskal—Wallis test. The differences
etween baseline and follow-up of all parameters in each
roup were also determined using the Kruskal—Wallis test.
hen differences were found, theWilcoxon—Mann—Whitney
est was used to test the signiﬁcance of the difference.
ategorical variables (incidence of hypertension, diabetes,
yslipidemia, and CIN, use of medications, gender, and
rocedure of CAG and/or PCI) were compared using the Chi-
quare test. Values of p < 0.05 were considered statistically
igniﬁcant. Statistical analysis was performed using StatView
-5.0 (SAS Institute Inc., Cary, NC, USA).
esults
atient characteristics
total of 45 patients were enrolled. Baseline patient
haracteristics are shown in Table 1. There were no CKD
atients. The number of patients with diabetes mellitus,
ypertension, or dyslipidemia was similar in each group,
s was the number receiving diuretics, calcium-channel
locker, or angiotensin II receptor antagonist before CAG
nd/or PCI. The volume of contrast agent used in the
roups was similar. The number of CAG and/or PCI in the
roups was also similar. No patients in this study devel-
ped acute nephrotoxicity requiring dialysis as a result
f the administration of contrast media. There were no
ajor adverse cardiac events throughout the study. Major
dverse cardiac events were deﬁned as cardiac death, non-
atal myocardial infarction (deﬁned as >3 times upper limit
f
t
i
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u337± 31.0 333± 91 0.657
BUN, blood urea nitrogen; SCr, serum creatinine; Ccr, creatinine
f creatine kinase-MB levels), or revascularization of the
arget lesion.
ncidence of CIN
e deﬁned CIN as an increase in SCr of more than 0.5mg/dl
rom baseline to 48 h after angiography. CIN occurred in 4
8.9%) of the 45 patients: 4 (26.7%) of the 15 patients in
he control group. There were no CIN patients in either
he NAC group or the aminophylline group (p = 0.0109; 95%
onﬁdence interval 0.102—5.991).
hanges in renal function
aseline BUN concentration was similar among the 3 groups.
n the control group, the mean BUN concentration signiﬁ-
antly increased from 12.0± 2.5 to 15.3± 2.5mg/dl at 48 h
fter CAG and/or PCI (p < 0.01). In the NAC group, the mean
UN concentration signiﬁcantly decreased from 13.8± 3.4
o 10.5± 1.5mg/dl (p < 0.01). In the aminophylline group,
he mean BUN concentration was unchanged (Fig. 1).
Baseline SCr concentration was similar among the 3
roups. In the control group, the mean SCr concentration
igniﬁcantly increased from 0.94± 0.21 to 1.28± 0.21mg/dl
p < 0.01), while in the NAC group, the mean SCr con-
entration signiﬁcantly decreased from 1.00± 0.36 to
.67± 0.16mg/dl (p < 0.01). In the aminophylline group, the
ean SCr concentration was unchanged (Fig. 2).
In the control group, themean Ccr signiﬁcantly decreasedrom 63.7± 16.1 to 46.1± 10.6ml/min (p < 0.01), while in
he NAC group, the mean Ccr concentration signiﬁcantly
ncreased from 62.4± 15.6 to 80.4± 8.39ml/min (p < 0.01).
n the aminophylline group, the mean Ccr concentration was
nchanged (Fig. 3).
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Figure 1 Changes in blood urea nitrogen (BUN) concentration
at baseline and at 48 h after CAG and/or PCI. Brackets represent
the standard deviation. Figure 4 Changes in blood beta-2 microglobulin at baseline
and at 48 h after CAG and/or PCI. Brackets represent the stan-
dard deviation.
Figure 5 Changes in urinary beta-2 microglobulin at base-
l
s
p
c
2Figure 2 Changes in serum creatinine (SCr) concentration at
baseline and at 48 h after CAG and/or PCI. Brackets represent
the standard deviation.
In the control group, the mean blood beta-2
microglobulin signiﬁcantly increased from 2.34± 0.48
to 2.97± 0.49mg/dl (p < 0.01), while in the NAC group, the
mean blood beta-2 concentration signiﬁcantly decreased
from 2.38± 0.58 to 1.71± 0.38mg/dl (p < 0.01). In the
aminophylline group, the mean blood beta-2 concentration
was unchanged (Fig. 4).
In the control group, the mean urinary beta-2
microglobulin concentration signiﬁcantly increased from
333± 69.7 to 513± 127g/ml (p < 0.01), while in the amino-
Figure 3 Changes in creatinine clearance (Ccr) at baseline
and at 48 h after CAG and/or PCI. Brackets represent the stan-
dard deviation.
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fine and at 48 h after CAG and/or PCI. Brackets represent the
tandard deviation.
hylline group, the mean urinary beta-2 microglobulin
oncentration signiﬁcantly decreased from 337± 31.0 to
39± 34g/ml (p < 0.01). In the NAC group, the mean uri-
ary beta-2 microglobulin concentration was unchanged
Fig. 5).
iscussion
he main conclusion of this study is that both prophylactic
AC and aminophylline administration are more effective in
reventing CIN than hydration alone in patients undergoing
AG and/or PCI. The use of these agents is inexpensive, safe,
mmediate, and thus useful in emergency situations. To our
nowledge, there have been no previous studies investigat-
ng the efﬁcacy of aminophylline in Japanese patients with
ormal renal function.
CIN may be caused by the direct toxic effects of the con-
rast medium on both tubular cells and glomeruli. Therefore
t seemed reasonable to investigate which segments of the
ephron are mostly damaged by the contrast medium. The
unction of glomeruli and tubules was checked by measuring
lood beta-2 microglobulin (a marker of glomerular func-
ion) and urinary beta-2 microglobulin (a marker of tubular
unction). There have been no previous studies investigating
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he efﬁcacy of NAC by evaluating blood and urinary beta-2
icroglobulin.
Iopamidol is a non-ionic low osmolar contrast media. It
s now well recognized that low osmolar contrast media
re less nephrotoxic than high osmolar contrast media
30]. In this study, patients in the control group showed
signiﬁcant increase in blood beta-2 microglobulin and
rinary beta-2 microglobulin concentration. These results
uggest that both glomerular and tubular injury may
ccur, even when a non-ionic low osmolar contrast media
s used.
Early administration of NAC prevents a reduction in
enal function in patients with acetaminophen poisoning
ho have liver failure [31]. A non-randomized study sug-
ested that NAC may improve renal function in patients
ith hepatorenal syndrome [32]. In the present study NAC
igniﬁcantly improved the renal function. These results
uggest that NAC may have a nephro-protective effect
eyond the prevention of CIN in patients with normal renal
unction.
NAC improves endothelium dependent vasomotion in the
oronary and peripheral circulation and is a potent antioxi-
ant that may scavenge a wide variety of oxygen-derived
ree radicals [26]. The ability of NAC to increase intra-
ellular and extracellular glutathione may be a crucial
actor in contrast-induced damage. Therefore, NAC may be
apable of preventing CIN by both improving renal hemody-
amic and preventing direct oxidative tissue damage [26].
atients receiving NAC showed a signiﬁcant decrease in
lood beta-2 microglobulin concentration, and an increase,
lthough insigniﬁcant, in urinary beta-2 microglobulin secre-
ion. These results suggest that the nephro-protective
ffect of NAC may be due mainly to its glomerular
rotection.
The nephro-protective effect of aminophylline is due
o its non-selective adenosine antagonism. Contrast media
smotically irritate tubulus cells. This results in adeno-
ine triphosphate turnover and the subsequent release of
denosine. In contrast to the other tissues in which adeno-
ine results in hyperemia, in the kidney, adenosine induces
arked vasoconstriction of the afferent arterioles via the
denosine-1-receptor [33]. In addition to the predominantly
lomerular protective effect of aminophylline, the urinary
eta-2 microglobulin data show that tubular protection also
s taking place, correlating with the ﬁndings of a recent
tudy. The urinary beta-2 microglobulin release is highly
orrelated with the initial tubular damage induced by the
ontrast medium. This tubuloprotective effect is more easily
nderstood in the light of the observations of the pre-
ious report by Humes et al. [33] that the tubulotoxic
ffects of contrast media can be augmented with hypoxia.
minophylline increases renal blood ﬂow by antagonizing
denosine receptors, and the higher renal blood ﬂow thus
rotects the tubulus cells.
These results suggest that NAC and aminophyline may
ct in different ways to prevent CIN. The combination of
AC and aminophylline seems to be superior to either NAC
r aminophylline alone. However, we did not examine the
ombination. There are still many uncertainties regarding
he efﬁcacy of NAC and aminophylline for CIN. Further stud-
es are needed to understand the pathophysiology of CIN in
etail.
[T. Kinbara et al.
tudy limitations
here are several limitations to this study, namely, the small
ample size and the fact that it was a single-center study,
hich may reduce the credibility of this study. The results
f the present study cannot be extended to patients at high
r very high risk of CIN. Finally, our data are limited to
he short term; the effect of NAC on long-term outcomes
emains unknown.
onclusions
his study suggests that both NAC and aminophylline
dministration for preventing CIN are more effective than
ydration alone in patients undergoing CAG and/or PCI. NAC
ppears mainly to produce a glomerular protective effect,
nd aminophylline to act through tubular protection.
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